retatrutide triple agonist weight loss trial 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 New Phase 3 retatrutide data

Modulation of the mTOR pathway has been shown to reduce inflammation, apoptosis, and oxidative stress following spinal cord injury, while promoting axonal regeneration (Wang et al., 2022)

Perform scheduled cleaning and descaling for consistent quality

As shown In Supplementary Figure 3 , qPCR analysis demonstrated that TB001 significantly reduced the mRNA expression levels of fibronectin (FN), -smooth muscle actin (-SMA), and vimentin compared with the vehicle-treated group

doi: 10.1038/ncomms3081

Why it's especially relevant for retatrutide Because retatrutide isn't approved yet, any "retatrutide for sale" to the general public is not coming through normal, regulated medicine supply chains